This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?
by Zacks Equity Research
ALNY stock soars 62% in a year, driven by increasing Amvuttra and Givlaari sales. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.
REGNNegative Net Change ALNYNegative Net Change NVSNegative Net Change RHHBYNegative Net Change
biotechnology biotechs medical pharmaceuticals
AMRN's Q4 Earnings Lag Estimates, Stock Down on Ratio Change Plan
by Zacks Equity Research
Amarin incurs a wider-than-expected loss in Q4. Revenues beat estimates. It plans to initiate a ratio change on its American Depositary Shares. Stock falls.
DVAXNegative Net Change BMRNNegative Net Change AMRNPositive Net Change ARVNPositive Net Change
biotechs earnings
Follow the Leader: 2 Biopharma Stocks Showing Relative Strength in 2025
by Bryan Hayes
Despite a correction to begin the year, there are a few pockets of the market that are working.
GILDNegative Net Change JAZZNegative Net Change
biotechnology biotechs cancer cell-therapy earnings immuno-therapy investing medical oncology-screening pharmaceuticals
How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma
by Sundeep Ganoria
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.
NVONegative Net Change LLYNegative Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Buy 3 Momentum Anomaly Stocks as Tariffs Take a Toll on Markets
by Supriyo Bose
MASI, HOOD and DFS are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
DFSNo Net Change MASIPositive Net Change HOODPositive Net Change
biotechs fin-tech finance
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More
by Ekta Bagri
TSVT and PTGX are in the spotlight this week following an acquisition agreement and study data, respectively.
BMYPositive Net Change GILDNegative Net Change PTGXPositive Net Change ARVNPositive Net Change
biotechnology biotechs medical pharmaceuticals
GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive
by Zacks Equity Research
Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the drug.
GSKPositive Net Change PFENo Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
SpringWorks Shares Rise More Than 30% in 3 Months: Here's Why
by Zacks Equity Research
SWTX's desmoid tumor drug, Ogsiveo, is driving its top line. The recent FDA nod for Gomekli to treat a rare tumor diversifies its commercial portfolio.
BMRNNegative Net Change XNCRPositive Net Change ANIXPositive Net Change SWTXPositive Net Change
biotechs
BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant
by Zacks Equity Research
BIIB's TRANSCEND phase III study on felzartamab in adult kidney transplant recipients diagnosed with late AMR is set to enroll approximately 120 patients.
NVSNegative Net Change BIIBNegative Net Change JAZZNegative Net Change ANIPNegative Net Change
biotechs
ARVN Stock Plunges 53% Following Mixed Data From Breast Cancer Study
by Zacks Equity Research
Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.
AZNPositive Net Change PFENo Net Change GILDNegative Net Change ARVNPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply
by Zacks Equity Research
The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its obesity drug VK2735.
NVONegative Net Change MRKPositive Net Change LLYNegative Net Change ABBVPositive Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono
by Zacks Equity Research
Per the deal terms, IONS will receive an upfront payment of $280 million from Ono. It is also eligible for milestone payments of up to $660 million.
AZNPositive Net Change GSKPositive Net Change BIIBNegative Net Change IONSNegative Net Change
biotechs medical pharmaceuticals
TSVT Up on Acquisition Agreement With BMY for $286 Million
by Zacks Equity Research
2seventy bio agrees to be acquired by partner BMY for $286 million. Shares gain.
REGNNegative Net Change BMYPositive Net Change NVONegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO Stock Down 9% as CagriSema Misses Target in Second Obesity Study
by Zacks Equity Research
Novo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second phase III study, missing the guidance of 25%.
BMRNNegative Net Change NVONegative Net Change GILDNegative Net Change CORTPositive Net Change
biotechnology biotechs medical pharmaceuticals
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
by Zacks Equity Research
The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.
BMYPositive Net Change JNJNegative Net Change BMRNNegative Net Change PTGXPositive Net Change
biotechs
BEAM Down Despite Positive Initial Data From Genetic Disorder Study
by Zacks Equity Research
Beam Therapeutics posts positive initial data from a phase I/II study investigating BEAM-302 for treating alpha-1 antitrypsin deficiency.
BMRNNegative Net Change BEAMPositive Net Change XNCRPositive Net Change ANIXPositive Net Change
biotechs
KOD Completes Enrollment in Phase III Study for Eye Disease Candidate
by Zacks Equity Research
Kodiak reports completing patient enrollment in its late-stage study evaluating tarcocimab for diabetic retinopathy.
BMRNNegative Net Change GILDNegative Net Change CORTPositive Net Change KODPositive Net Change
biotechnology biotechs medical pharmaceuticals
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study
by Zacks Equity Research
Data from a mid-stage study shows that treatment with Trevi's experimental drug reduced patients' 24-hour cough frequency by 57% over placebo.
GSKPositive Net Change MRKPositive Net Change TRVINegative Net Change
biotechs medical pharmaceuticals
Buy 5 Non-Tech High-Flying Nasdaq Stocks Amid Index's Recent Bloodbath
by Nalak Das
We have narrowed our search to five Nasdaq Composite-listed non-tech stocks that have provided double-digit returns year to date. These are: EXC, GILD, PAA, SRAD, CTAS.
EXCNegative Net Change PAANegative Net Change GILDNegative Net Change CTASPositive Net Change SRADPositive Net Change
biotechs business-services consumer-discretionary oil-energy utilities
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe
by Zacks Equity Research
The latest decision makes Ionis/AstraZeneca's Wainzua the only approved drug in the EU for ATTRv-PN that can be self-administered monthly via an auto-injector.
AZNPositive Net Change GSKPositive Net Change BIIBNegative Net Change IONSNegative Net Change
biotechs medical pharmaceuticals
Bristol Myers Stock Gains 9.2% in a Month: Should You Buy Now or Wait?
by Ekta Bagri
BMY is banking on new drugs to offset generic competition for older drugs. However, this might not be enough as the outlook for 2025 is weak. We recommend investors to wait.
BMYPositive Net Change PFENo Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies
by Zacks Equity Research
Incyte reports positive data from two phase III studies evaluating Opzelura for prurigo nodularis in adults.
BMRNNegative Net Change GILDNegative Net Change INCYNegative Net Change CORTPositive Net Change
biotechnology biotechs medical pharmaceuticals
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC
by Zacks Equity Research
The EC approves BMY's combination of Opdivo and Yervoy for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.
BMYPositive Net Change BMRNNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies
by Zacks Equity Research
Data from two more late-stage studies show that treatment with Amgen's rocatinlimab improves outcomes in atopic dermatitis indication.
REGNNegative Net Change SNYNegative Net Change AMGNPositive Net Change
biotechs medical pharmaceuticals
LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study
by Zacks Equity Research
Eli Lilly and INCY announce positive efficacy data from the late-stage alopecia study of baricitinib in adolescent patients.
BMRNNegative Net Change LLYNegative Net Change GILDNegative Net Change INCYNegative Net Change
biotechnology biotechs medical pharmaceuticals